Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension

被引：41

作者：

Nikkho, Sylvia M. ^{[1
]}

Richter, Manuel J. ^{[2
,3
]}

Shen, Eric ^{[4
]}

Abman, Steven H. ^{[5
,6
]}

Antoniou, Katerina ^{[7
]}

Chung, Jonathan ^{[8
]}

Fernandes, Peter ^{[9
]}

Hassoun, Paul ^{[10
]}

Lazarus, Howard M. ^{[11
]}

Olschewski, Horst ^{[12
]}

Piccari, Lucilla ^{[13
]}

Psotka, Mitchell ^{[14
,15
]}

Saggar, Rajan ^{[16
]}

Shlobin, Oksana A. ^{[17
]}

Stockbridge, Norman ^{[15
]}

Vitulo, Patrizio ^{[18
]}

Vizza, Carmine Dario ^{[19
]}

Wort, Stephen J. ^{[20
,21
]}

Nathan, Steven D. ^{[17
]}

机构：

[1] Bayer AG, Global Clin Dev, Berlin, Germany

[2] Univ Giessen, Dept Internal Med, Pulm Hypertens Div, Giessen, Germany

[3] Univ Marburg, Lung Ctr UGMLC, Giessen, Germany

[4] United Therapeut Corp, Global Med Affairs, Silver Spring, MD USA

[5] Univ Colorado, Sch Med, Anschutz Med Campus, Aurora, CO USA

[6] Univ Colorado, Childrens Hosp, Anschutz Med Campus, Aurora, CO USA

[7] Univ Crete, Sch Med, Dept Thorac Med, Iraklion, Crete, Greece

[8] Univ Chicago Med, Dept Radiol, Chicago, IL USA

[9] Bellerophon Therapeut Inc, Regulatory Safety & Qual Dept, Warren, NJ USA

[10] Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA

[11] Altavant Sci, Cary, NC USA

[12] Med Univ Graz, Dept Internal Med, Div Pulmonol, Graz, Steiermark, Austria

[13] Hosp del Mar, Dept Pulm Med, Pulm Hypertens Unit, Barcelona, Catalunya, Spain

[14] Inova Heart & Vasc Inst, Falls Church, VA USA

[15] US FDA, Div Cardiol & Nephrol, Silver Spring, MD USA

[16] Univ Calif Los Angeles, David Geffen Sch Med, Lung & Heart Lung Transplant & Pulm Hypertens Pro, Los Angeles, CA 90095 USA

[17] Inova Heart & Vasc Inst, Adv Lung Dis & Transplant Program, Falls Church, VA 22042 USA

[18] IRCCS Mediterranean Inst Transplantat & Adv Speci, Dept Pulm Med, Therapies, Palermo, Sicilia, Italy

[19] Univ Roma La Sapienza, Pulm Hypertens Unit, Rome, Lazio, Italy

[20] Royal Brompton Hosp, Natl Pulm Hypertens Serv, London, England

[21] Imperial Coll, Natl Heart & Lung Inst, London, England

来源：

PULMONARY CIRCULATION | 2022年 / 12卷 / 03期

关键词：

epidemiology; interstitial lung disease; prognosis; pulmonary hypertension; symptom assessment and management; EXERCISE CAPACITY; INHALED ILOPROST; NITRIC-OXIDE; FIBROSIS; PREVALENCE; EPIDEMIOLOGY; SILDENAFIL; UPDATE; VASOCONSTRICTION; PROSTACYCLIN;

D O I：

10.1002/pul2.12127

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly associated with decreased exercise and functional capacity, an increased risk of hospitalizations and death. Examining the scope of this issue and its impact on patients is the first step in trying to define a roadmap to facilitate and encourage future research in this area. The aim of our working group is to strengthen the communities understanding of PH due to lung diseases and to improve the care and quality of life of affected patients. This introductory statement provides a broad overview and lays the foundation for further in-depth papers on specific topics pertaining to PH-ILD.

引用

页数：16

共 90 条

[1] HYPOXIC PULMONARY VASOCONSTRICTION AND GAS-EXCHANGE DURING EXERCISE IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].

AGUSTI, AGN ;

BARBERA, JA ;

ROCA, J ;

WAGNER, PD ;

GUITART, R ;

RODRIGUEZROISIN, R .

CHEST, 1990, 97 (02) :268-275

[2] Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension [J].

Alhamad, Esam H. ;

Cal, Joseph G. ;

Alrajhi, Nuha N. ;

Alharbi, Waleed M. .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12)

[3]

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]

[4] Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE) [J].